# A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

Journal of Diabetes Science and Technology 2023, Vol. 17(5) 1226–1242 © 2022 Diabetes Technology Society Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/19322968221085273 journals.sagepub.com/home/dst



#### Abstract

**Background:** A composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful for assisting with basic clinical interpretation of CGM data.

**Methods:** We assembled a data set of 14-day CGM tracings from 225 insulin-treated adults with diabetes. Using a balanced incomplete block design, 330 clinicians who were highly experienced with CGM analysis and interpretation ranked the CGM tracings from best to worst quality of glycemia. We used principal component analysis and multiple regressions to develop a model to predict the clinician ranking based on seven standard metrics in an Ambulatory Glucose Profile: very low–glucose and low-glucose hypoglycemia; very high–glucose and high-glucose hyperglycemia; time in range; mean glucose; and coefficient of variation.

**Results:** The analysis showed that clinician rankings depend on two components, one related to hypoglycemia that gives more weight to very low-glucose than to low-glucose and the other related to hyperglycemia that likewise gives greater weight to very high-glucose than to high-glucose. These two components should be calculated and displayed separately, but they can also be combined into a single Glycemia Risk Index (GRI) that corresponds closely to the clinician rankings of the overall quality of glycemia (r = 0.95). The GRI can be displayed graphically on a GRI Grid with the hypoglycemia component on the horizontal axis and the hyperglycemia component on the vertical axis. Diagonal lines divide the graph into five zones (quintiles) corresponding to the best (0th to 20th percentile) to worst (81st to 100th percentile) overall quality of glycemia. The GRI Grid enables users to track sequential changes within an individual over time and compare groups of individuals.

**Conclusion:** The GRI is a single-number summary of the quality of glycemia. Its hypoglycemia and hyperglycemia components provide actionable scores and a graphical display (the GRI Grid) that can be used by clinicians and researchers to determine the glycemic effects of prescribed and investigational treatments.

#### Keywords

ambulatory glucose profile, composite metric, continuous glucose monitor, diabetes, glycemia risk index, hyperglycemia, hypoglycemia, time in range

<sup>1</sup>Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA <sup>2</sup>Florida State University College of Nursing, Tallahassee, FL, USA <sup>3</sup>Biomedical Informatics Consultants LLC, Potomac, MD, USA <sup>4</sup>University of California, San Francisco, San Francisco, CA, USA <sup>5</sup>University of California, Berkeley, Berkeley, CA, USA <sup>6</sup>Sansum Diabetes Research Institute, Santa Barbara, CA, USA <sup>7</sup>Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA <sup>8</sup>University of Southern California, Los Angeles, CA, USA <sup>9</sup>Emory University, Atlanta, GA, USA <sup>10</sup>Weill Cornell Medicine, New York, NY, USA <sup>11</sup>Diabetes Technology Society, Burlingame, CA, USA <sup>12</sup>International Diabetes Center, Minneapolis, MN, USA <sup>13</sup>Boston Children's Hospital, Harvard Medical School, Boston, MA, USA <sup>14</sup>King Saud University, Riyadh, Saudi Arabia <sup>15</sup>Johns Hopkins University, Baltimore, MD, USA <sup>16</sup>UT Health San Antonio, San Antonio, TX, USA <sup>17</sup>AMCR Institute, Escondido, CA, USA <sup>18</sup>University of Virginia, Charlottesville, VA, USA <sup>19</sup>Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia <sup>20</sup>Addis Ababa University, Addis Ababa, Ethiopia <sup>21</sup>Centre Hospitalier Universitaire de Grenoble, Grenoble, France <sup>22</sup>Rensselaer Polytechnic Institute, Troy, NY, USA <sup>23</sup>Texas Diabetes and Endocrinology, Austin, TX, USA <sup>24</sup>Oregon Health & Science University, Portland, OR, USA <sup>25</sup>University of Canterbury, Christchurch, New Zealand <sup>26</sup>National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA <sup>27</sup>University of Leicester, Leicester, UK <sup>28</sup>Children's Mercy Hospital, Kansas City, MO, USA <sup>29</sup>Close Concerns, San Francisco, CA, USA <sup>30</sup>Mayo Clinic Arizona, Scottsdale, AZ, USA <sup>31</sup>Diabetes Center Auf der Bult, Hannover Medical School, Hannover, Germany <sup>32</sup>Harvard University, Cambridge, MA, USA <sup>33</sup>University of Nebraska, Omaha, NE, USA <sup>34</sup>The Ohio State University, Columbus, OH, USA <sup>35</sup>University of California, San Diego, San Diego, CA, USA <sup>36</sup>Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark

# Introduction

Continuous glucose monitor (CGM) data is emerging as a useful tool for assessing and quantifying the quality of glycemic control.<sup>1</sup> Glycemic control encompasses the risk of both acute hypoglycemia and chronic hyperglycemia,<sup>2</sup> which is in turn associated with long-term complications.<sup>3</sup> Clinicians and patients would benefit from CGM metrics that characterize the proportions of time with both very low/low, and high/very high glucose concentrations, a concept which can be termed "quality of glycemia."

A widely used report recommended in the American Diabetes Association (ADA) Standards of Medical Care in Diabetes–2022<sup>4</sup> for summarizing the results of CGM tracings is the Ambulatory Glucose Profile (AGP),<sup>5</sup> which presents seven key metrics from a CGM tracing.<sup>6,7</sup> These metrics include the following:

<sup>37</sup>Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA <sup>38</sup>Kinexum, Harpers Ferry, WV, USA <sup>39</sup>Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO, USA <sup>40</sup>Institute for Diabetes-Technology GmbH, Ulm, Germany <sup>41</sup>Pontificia Universidad Javeriana, Bogotá, Colombia <sup>42</sup>Science Consulting in Diabetes GmbH, Kaarst, Germany <sup>43</sup>University of Washington, Seattle, WA, USA <sup>44</sup>Walter Reed National Military Medical Center, Bethesda, MD, USA <sup>45</sup>University of Cambridge, Cambridge, UK <sup>46</sup>Örebro University, Örebro, Sweden <sup>47</sup>Peking University People's Hospital, Peking University Diabetes Center, Beijing, China <sup>48</sup> Joshi Clinic, Mumbai, India <sup>49</sup>Caen University Hospital, Caen, France <sup>50</sup>Stanford University, Stanford, CA, USA <sup>51</sup>Cleveland Clinic, Cleveland, OH, USA <sup>52</sup>Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA <sup>53</sup>LAC + USC Medical Center, Los Angeles County Department of Health Service, Los Angeles, CA, USA <sup>54</sup>Manchester University NHS Foundation Trust and The University of Manchester, Manchester, UK <sup>55</sup>Li Ka Shing Knowledge Institute, St. Michael's Hospital and University of Toronto, Toronto, ON, Canada  $^{\rm 56} {\rm University}$  of Gothenburg, Gothenburg, Sweden <sup>57</sup>The University of Utah College of Nursing, Salt Lake City, UT, USA <sup>58</sup>Medical University of Graz, Graz, Austria <sup>59</sup>National Healthcare University of Ukraine, Kiev, Ukraine <sup>60</sup>Endocrinology Research Centre, Moscow, Russian Federation <sup>61</sup>Morton Plant Hospital, Clearwater, FL, USA <sup>62</sup>Stony Brook University, Stony Brook, NY, USA <sup>63</sup>Dr. Mohan's Diabetes Specialities Centre, Chennai, India <sup>64</sup>Madras Diabetes Research Foundation, Chennai, India <sup>65</sup>Vanderbilt University Medical Center, Nashville, TN, USA <sup>66</sup>Steno Diabetes Center Copenhagen, Herlev, Denmark <sup>67</sup>University of Melbourne, Melbourne, VIC, Australia <sup>68</sup>Scripps Whittier Diabetes Institute, San Diego, CA, USA <sup>69</sup>Institute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel <sup>70</sup>Behavioral Diabetes Institute, San Diego, CA, USA <sup>71</sup>University of Michigan, Ann Arbor, MI, USA <sup>72</sup>Ipswich Hospital, East Suffolk and North Essex Foundation Trust and University of East Anglia, Ipswich, UK <sup>73</sup>Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Korea <sup>74</sup>Massachusetts General Hospital Diabetes Research Center, Boston, MA, USA <sup>75</sup>Yale University, New Haven, CT, USA <sup>76</sup>The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA <sup>77</sup>North Carolina State University, Raleigh, NC, USA <sup>78</sup>University of Maryland, Baltimore, MD, USA <sup>79</sup>The University of Edinburgh, Edinburgh, UK <sup>80</sup>The University of Tokyo, Tokyo, Japan <sup>81</sup>Northwestern University, Chicago, IL, USA <sup>82</sup>California Pacific Medical Center, San Francisco, CA, USA <sup>83</sup>Boston Medical Center, Boston, MA, USA <sup>84</sup>Charlotte AHEC, Charlotte, NC, USA <sup>85</sup>Johns Hopkins Community Physicians, Bethesda, MD, USA **Corresponding Author:** 

David C. Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE, Diabetes Research Institute, Mills-Peninsula Medical Center, 100 South San Mateo Drive, Room 5147, San Mateo, CA 94401, USA. Email: dklonoff@diabetestechnology.org Percentages of time in:

- very low-glucose hypoglycemia (VLow: <54 mg/ dL; <3.0 mmol/L) (level 2 hypoglycemia)</li>
- low-glucose hypoglycemia (Low: 54-<70 mg/dL; 3.0-<3.9 mmol/L) (level 1 hypoglycemia)</li>
- 3. target range (TIR: 70-180 mg/dL; 3.9-10.0 mmol/L),
- high-glucose hyperglycemia (High: >180-250 mg/ dL; >10.0-13.9 mmol/L) (level 1 hyperglycemia)
- 5. very high–glucose hyperglycemia (VHigh: >250 mg/dL; >13.9 mmol/L) (level 2 hyperglycemia)

as well as

- 6. coefficient of variation (CV) (standard deviation / mean glucose)
- mean glucose (MG) as well as the glucose management indicator (GMI), which is a measure linearly related to MG<sup>5</sup>

These seven metrics are highly interdependent. For example, the five percent-of-time metrics cover 100% of the monitoring period so that any one of them can be determined by subtracting the other four from 100%. The time in very low-glucose (VLow) plus the time in low-glucose (Low) is the time below range (TBR). The time in very high-glucose (VHigh) plus the time in high-glucose (High) is the time above range (TAR). In an AGP report, these seven metrics are each typically presented with a target range. To interpret a CGM profile, a clinician must simultaneously process these seven metrics, along with an aggregated 14-day glucose profile (but other measurement durations could also be used now or in the future) to determine the quality of glycemia. Interdependence means that if a clinician tries to improve one metric, for example, TIR, then other metrics might improve or worsen. This makes the treatment optimization task difficult and unpredictable because it is unlikely for all metrics associated with an AGP to improve simultaneously.

### Metrics for Glycemic Control

The ADA Standards of Care state that the TIR as measured by a CGM can be used for assessment of glycemic control.<sup>4</sup> Many clinicians use this single number as a guide to the quality of a patient's glycemia. However, use of TIR in this context has been criticized for not being adequately sensitive to hypoglycemia.<sup>8,9</sup> As an alternative to TIR, several composite scores have been proposed to combine measures of glycemic control.<sup>9,10</sup> However, some of these scores may not adequately reflect both hypoglycemia and hyperglycemia or provide greater weighting for time in VLow than time in Low, or for time in VHigh than time in High.<sup>11</sup>

In this study, we (1) identify the two essential components that best present a person's glycemic state—one responsible for the risk of hypoglycemia and the other responsible for exposure to hyperglycemia, based on a graphical and numerical interpretation of AGP data, and (2) introduce a composite metric that describes the quality of a CGM wearer's glycemic control in a single score weighted according to the risk for hypoglycemia and hyperglycemia, based on their importance as systematically evaluated by a large number of experienced clinicians. Such a metric would provide clinicians with a single number accounting for the principal dimensions of their patients' glycemic control and would facilitate review of multiple CGM reports over time.

### Methods

### Design

We developed a model to predict the rankings by experienced clinicians of 14-day CGM tracings. The study was approved by the University of Texas San Antonio Health Science Center Institutional Review Board.

### Data Set of Continuous Glucose Monitor Tracings

We assembled a de-identified data set of 14-day CGM tracings from 225 adults with diabetes that had been used in the DIAMOND,<sup>12</sup> DCLP3,<sup>13</sup> REPLACE-BG,<sup>14</sup> and DIAMOND T2D<sup>15</sup> Trials. The CGMs used were Dexcom G4 Platinum CGM Systems with an enhanced algorithm (software 505)<sup>12,14,15</sup> and Dexcom G6 sensors<sup>13</sup> (Dexcom Inc., San Diego, CA, USA) with the same format for displaying trend data. The CGM tracings were from subjects in four categories: type 1 diabetes (T1D) using (1) hybrid closed loop (HCL), (2) insulin infusion pump (Pump), (3) multiple daily insulin injections (MDI), or (4) type 2 diabetes (T2D) using MDI. The types of subjects in each of the four trials included the following: DIAMOND12 (T1D MDI users-blinded runin for 14 days); DCLP313 (T1D MDI users-either prestudy personal CGM data for MDI users using Dexcom CGM or unblinded run-in data for 14 days collected while using MDI prior to starting Pump, and T1D HCL users-unblinded CGM while using Control IQ [Tandem, San Diego, CA, USA]); REPLACE-BG<sup>14</sup> (T1D Pump users-baseline data which was either prestudy personal CGM or run-in phase blinded or unblinded CGM), and DIAMOND T2D<sup>15</sup> (T2D MDI users—blinded baseline data). Each patient category was represented by 56 CGM tracings, except for T2D, which had 57 CGM tracings. Every CGM tracing contained at least 92% of the potential data points.

## Clinician Rankers

We invited 330 expert diabetologists from six continents who reported reviewing at least 20 CGM tracings per month in their clinical practice. These clinicians ranked the 225 CGM tracings from best to worst in terms of the quality of their glycemia. The geographic locations and specialties of the clinicians are presented in Supplementary Tables S1a and S1b. In pretesting, we determined that each clinician could compare five CGM tracings at a time, so we used an incomplete block design with a block size of five.<sup>16-18</sup> For the incomplete block design to be balanced, each possible pair of CGM tracings should appear in the same number of blocks, such that any given 14-day CGM tracing is compared against all other CGM tracings the same number of times—in this case, two times. Details of the balanced, incomplete block design and assessment of inter-rater agreement are provided in the Supplementary Material. Ultimately, each of the 225 CGM tracings appeared in 22 separate blocks, and each received 22 independent rankings on a scale ranging between 0 and 4. The rankings were based on the CGM tracings alone without additional instructions. The format for the CGM tracings was identical, regardless of CGM make/model. The 225 CGM tracings were sorted by average ranking, normalized so that each tracing was assigned a percentile score ranging from 0 to 100, with 0 representing "best" or "no risk" and 100 representing "worst" or "maximum risk." This clinicians' percentile ranking was the quantity that the new composite index, the Glycemia Risk Index (GRI), was intended to predict. We then sought to find the best model to predict the clinicians' percentile rankings for each subject using the seven available CGM metrics from an AGP report.

# Modeling Approach

To uncover the essential components of glycemic control, we applied principal component analysis (PCA) for dimensionality reduction and variable selection. We also compared each individual metric to the clinician rankings. To develop the model, we used five-fold cross-validation with recursive feature elimination to determine the optimal number of metrics to include and to inform variable selection.<sup>19</sup> In addition, we used linear regression–based variable selection approaches, including forward, backward, stepwise, and Lasso regressions.<sup>20</sup> We also used two machine learning feature selection methods, Boruta<sup>21</sup> and recursive partitioning,<sup>22,23</sup> to evaluate the relative importance of input variables. We considered nonlinear relationships, while endeavoring to achieve a balance between model simplicity and goodness-of-fit.

# Statistical Analysis

We summarize each of the seven AGP metrics with mean, standard deviation (SD), median, 25th/75th percentile, minimum, and maximum, calculated for the entire set of 225 CGM tracings and for the CGM tracings stratified by the four patient categories. For all bivariate comparisons between metrics, we display scatterplots and report correlation coefficients. The PCA results are summarized in a correlation matrix. We then consider the clinicians' percentile rankings, reporting bivariate comparisons between each metric and clinician rankings using scatterplots and correlation coefficients. Finally, we present the newly proposed metric, GRI. Goodness-of-fit for alternative models is summarized with the correlation coefficient, adjusted  $R^2$  (Adj  $R^2$ ), and root mean square error (RMS). We evaluated goodness-of-fit for all subjects combined and for each of the four patient categories. We evaluated statistical significance of models involving different numbers of input variables (regression coefficients) and degrees of freedom using the extra sum of squares principle.<sup>24</sup>

# Results

# Data Set of Continuous Glucose Monitor Tracings

The 225 CGM tracings showed wide variation in all seven AGP metrics. For example, MG ranged from 94 to 267 mg/ dL (5.2-14.8 mmol/L) and VHigh ranged from 0% to 57% of the time (Table 1, Supplementary Figure S1). The category of persons with T1D using MDI had the worst quality of glycemia as evidenced by highest average time in VLow (2.5%), lowest average TIR (43.9%), highest average time in VHigh (23.7%), and highest MG (188 mg/dL; 10.4 mmol/L) (Supplementary Table S2).

# Principal Component Analysis

The PCA showed that the seven metrics can be divided into two distinct, highly correlated groups or clusters: a hypoglycemia-related group (including VLow, Low, and CV) and a hyperglycemia-related group (including VHigh, High, TIR, and MG) (Figure 1). These two clusters, which involve three and four metrics (hypoglycemia and hyperglycemia, respectively), explain 88% of the variance in the clinicians' percentile rankings for all 225 CGM tracings. Thus, two essential components account for nearly 90% of the variability in the seven AGP metrics.

A criticism of TIR as a single metric is that it is not sensitive to hypoglycemia.<sup>8</sup> In our CGM data set, the correlation between TIR and VLow was -0.11 (Figure 1) and the correlation between TIR and TBR (VLow + Low) was found to be 0.01.

# Development of the GRI

The clinicians' rankings were used to assign each CGM tracing a percentile score ranging from 0 to 100, with 0 representing "best" or "no risk" and 100 representing "worst" or "maximum risk." This clinicians' percentile ranking was the quantity that we sought to predict with the GRI.

Multifold cross-validation determined that the optimal number of features, balancing bias and variance, was four. Because the AGP's five percent-of-time metrics sum to 100%, they are exactly collinear. A linear regression model that includes two or more exactly collinear variables will not

	Overall (N = 225)		Min.	Percentile			Max.
	Avg	SD	Oth	25th	50th	75th	100th
% of time							
Very Low (<54 mg/dL; <3.0 mmol/L)	1.2	2.0	0	0	0	I	12
Low (54-<70 mg/d; 3.0-<3.9 mmol/L)	2.5	2.8	0	0	2	4	15
In Range (70-180 mg/dL; 3.9-10.0 mmol/L)	59.9	21.2	13	42	59	80	97
High (>180-250 mg/dL; > 10.0-13.9 mmol/L)	23.4	11.5	I	14	23	32	58
Very High (>250 mg/dL; >13.9 mmol/L)	13.0	12.9	0	2	10	21	57
Total	100.0						
Other							
Mean Glucose (mg/dL)	167	34	94	140	161	192	267
Coefficient of Variation	0.35	0.08	0.18	0.29	0.33	0.40	0.62

Table I. Summary of Ambulatory Glucose Profile Metrics for 225 Continuous Glucose Monitor Tracings.

								1.00
TIR	1	-0.94	-0.83	-0.91	-0.27	0.1	-0.11	-0.75
MG	-0.94	1	0.8	0.93	0.052	-0.38	-0.16	-0.50
High	-0.83	0.8	1	0.58	-0.083	-0.41	-0.18	-0.25
VHigh	-0.91	0.93	0.58	1	0.25	-0.13	0.03	-0.00
S	-0.27	0.052	-0.083	0.25	1	0.73	0.74	0.25
Low	0.1	-0.38	-0.41	-0.13	0.73	1	0.75	0.50
VLow	-0.11	-0.16	-0.18	0.03	0.74	0.75	1	0.75
	TIR	MG	High	VHigh	CV	Low	VLow	-1.00

**Figure 1.** Correlation between pairs of metrics, where 1.0 indicates a strong correlation and -1.0 indicates a strong inverse correlation. The principal component analysis showed that the seven metrics divide into two highly correlated groups: a hypoglycemia-related group (including VLow, Low, and CV) and a hyperglycemia-related group (including VHigh, High, TIR, and MG). Therefore, each group of metrics is represented by one principal dimension, or essential component, of the quality of glycemia (the hypoglycemia component and the hyperglycemia component). Abbreviations: VLow, <54 mg/dL; <3.0 mmol/L; Low, 54-<70 mg/dL; 3.0-<3.9 mmol/L; CV, coefficient of variation (standard deviation of glucose/mean glucose); VHigh, >250 mg/dL; >13.9 mmol/L; High, >180-250 mg/dL; >10.0-13.9 mmol/L; TIR, time in target range (70-180 mg/dL; 3.9-10.0 mmol/L); MG, mean glucose (mg/dL).

produce a solution. Therefore, it was necessary to remove one of the five percent-of-time metrics from our model so that the four remaining variables would not add up to 100%. Ultimately, we removed TIR. This is because TIR is highly negatively correlated (r = -0.91) with the VHigh metric, so only one of the two should be included in the model. Both forward and backward stepwise regression retained VHigh in preference to TIR. We also used two machine learning feature selection methods, Boruta and recursive partitioning; both methods indicated that VHigh was more important than TIR. Although not specifically included in our model, TIR is included implicitly since it can be calculated from the other four percent-of-time metrics: TIR = 100% - (VHigh + High+ Low + VLow). MG was highly correlated with the other hyperglycemia metrics, but was the least important metric in several variable selection methods including recursive feature elimination, forward and backward stepwise regression, and LASSO regression. Similarly, the CV was highly correlated with the hypoglycemia metrics. Of the three correlated hypoglycemia metrics, we chose to retain VLow and Low in preference to the CV because VLow and Low are more clearly actionable metrics. The CV is the ratio of the SD of the glucose concentrations (a marker of variability with a known relationship to hypoglycemia) divided by MG (an indirect marker of hyperglycemia). Whereas both SD and MG will be lower with optimal treatment, their ratio would not necessarily decrease. Furthermore, the variance inflation factor (VIF) associated with retaining the CV in the model was 13.7. This VIF greater than 10 indicates that CV was strongly correlated with the other four metrics (Low, VLow, High, and VHigh) and could be eliminated from the model.<sup>21</sup> After eliminating TIR, MG, and CV, we were left with Low, VLow, High, and VHigh as the four essential parameters (independent variables) in our model. These four metrics are well established and clinically actionable.5

Using both the PCA results and clinical reasoning, we combined VLow and Low into a unified hypoglycemia component, and similarly, VHigh and High into a unified hyperglycemia component. For both of these essential components, we assigned full weight (coefficient of 1) to the percent of time with the more extreme abnormality and a reduced weight (coefficient < 1) to the percent of time with the less extreme abnormality. This is a common weighting technique that has been used with glucose data for more than 20 years.<sup>25</sup> By construction, neither component can exceed 100%. Based Table 2. Formula for Calculating the Glycemia Risk Index.

VLow = very low-glucose hypoglycemia (% of time) Low = low-glucose hypoglycemia (% of time) VHigh = very high-glucose hyperglycemia (% of time) High = high-glucose hyperglycemia (% of time) Hypoglycemia Component =  $VLow + (0.8 \times Low)$ (Equation #1) Hyperglycemia Component =  $VHigh + (0.5 \times High)$ (Equation #2)  $GRI = (3.0 \times HypoComponent) + (1.6 \times HyperComponent)$ (Equation #3) Equivalently,  $GRI = (3.0 \times VLow) + (2.4 \times Low) + (1.6 \times VHigh) + (0.8 \times High)$ (Equation #4) Example: VLow = 5%, Low = 10%, VHigh = 15%, High = 20% HypoComponent =  $5\% + (0.8 \times 10\%) = 13\%$ (Equation #1) HyperComponent =  $15\% + (0.5 \times 20\%) = 25\%$ (Equation #2)  $GRI = (3.0 \times 13\%) + (1.6 \times 25\%) = 79$ (Equation #3) Equivalently,  $GRI = (3.0 \times 5\%) + (2.4 \times 10\%) + (1.6 \times 15\%) + (0.8 \times 20\%) =$ GRI = 15 +24 +24 +16 = 79 In this example TIR = 100% - (VLow + Low + VHigh + High)= 100% - (5% + 10% + 15% + 20%)= 100 - 50%= 50%

Abbreviations: GRI, Glycemia Risk Index; VLow, very low–glucose hypoglycemia (<54 mg/dL; <3.0 mmol/L) (level 2 hypoglycemia); Low, low-glucose hypoglycemia (54-<70 mg/dL; 3.0-<3.9 mmol/L) (level 1 hypoglycemia); TIR, time in target range (70-180 mg/dL; 3.9-10.0 mmol/L); High, high-glucose hyperglycemia (>180-250 mg/dL; >10.0-13.9 mmol/L) (level 1 hyperglycemia); VHigh, very high–glucose hyperglycemia (>250 mg/dL; >13.9 mmol/L) (level 2 hyperglycemia); VHigh, very high–glucose hyperglycemia (>250 mg/dL; >13.9 mmol/L) (level 2 hyperglycemia); VHigh, very high–glucose hyperglycemia (>250 mg/dL; >13.9 mmol/L) (level 2 hyperglycemia); VHigh, very high–glucose hyperglycemia (>250 mg/dL; >13.9 mmol/L) (level 2 hyperglycemia).


on the ratio of the coefficients in the linear regression model with the clinicians' percentile ranking as the dependent variable and VLow, Low, High, and VHigh as the independent variables, we determined a weight for Low of 0.8 of VLow (Table 2, Equation #1), and a weight for High of 0.5 of VHigh (Table 2, Equation #2). Since these coefficient values were based on the ratio of the best-fit regression coefficients, they reflect the combined judgment of the clinicians about the relative importance of less extreme versus more extreme abnormalities. The GRI is then calculated as a linear combination of the two essential components, which represent hypoglycemia and hyperglycemia. Using a linear regression model with the clinicians' percentile ranking as the dependent variable and the hypoglycemia and hyperglycemia components as the independent variables, we found the best-fit coefficients for the hypoglycemia and hyperglycemia components to be 3.0 and 1.6, respectively. The model formula based on predicted clinician rankings is presented in Table 2.

This model was designed to give a best-fit, unbiased estimate of the clinicians' percentile rankings, meaning that it fits the rankings well and is equally likely to underestimate or overestimate the ranking (Figure 2). Although the GRI's hypoglycemia and hyperglycemia components cannot exceed 100%, a calculated GRI exceeding 100 is arithmetically possible if a CGM tracing would receive a high clinician ranking close to 100 with overestimation by the model. If Equation #4 exceeds 100, then the GRI is capped at 100.

The GRI predicts the clinicians' percentile rankings. It is calculated as  $GRI = (3.0 \times VLow) + (2.4 \times Low) + (1.6 \times VHigh) + (0.8 \times High)$ , with a maximum permissible value of 100.

## Correlation of the GRI With Other Metrics

Since the GRI was designed to estimate the clinicians' percentile rankings (with 0 being the best and 100 being the worst), it is not surprising that the GRI fits those rankings better than any of the seven individual metrics reported with the AGP. The correlation between the seven AGP metrics and clinician rankings are illustrated in Figure 3 and Supplementary Figure S2. For example, as TIR decreases, the clinicians' percentile ranking increases, and compared with the GRI, TIR does not correlate as well with the clinicians' percentile rankings (TIR:  $R^2 = 0.824$ , RMS = 12.16; GRI:  $R^2 = 0.904$ , RMS = 8.95; P < .00001 by extra sum of squares). When TIR was approximately 50%, the clinicians' percentile ranking could be as high as 97 or as low as 44. Similarly, when TIR was approximately 70%, the clinicians' percentile ranking could be as high as 62 or as low as 25




**Figure 2.** Relationship between clinicians' percentile rankings and the Glycemia Risk Index. Each individual clinician's data point is represented as a blue dot. The 95% confidence interval is in solid yellow lines and the 95% prediction interval is in the dashed line. Abbreviations: GRI, Glycemia Risk Index; CGM, continuous glucose monitor; RMS, root mean square error.

(Figure 3). This discrepancy in the clinicians' percentile rankings for a given TIR reflects (1) differences in how much of the time out of range was hypoglycemia versus hyperglycemia and (2) the relative contributions of Low, VLow, High, and VHigh. These factors are incorporated into the GRI, but are not reflected in TIR.

Since the GRI is based on weighted combinations of TBR (the hypoglycemia component) and TAR (the hyperglycemia component), like the clinicians' percentile rankings, the GRI is high when TIR is low. The correlation coefficient between the GRI and TIR is -0.91 (Figure 1).

TBR (VLow + Low) combined with TIR is an established combination of metrics that can be an effective basis for interventions to improve the quality of glycemia.<sup>26</sup> We considered a model based on an optimized combination of TBR and TIR. However, this model of a composite metric did not fit the clinicians' rankings quite as well as the GRI in terms of adjusted R<sup>2</sup> and RMS. (TBR/TIR: Adj R<sup>2</sup> = 0.889; RMS = 9.64; GRI: Adj R<sup>2</sup> = 0.904, RMS = 8.95, P < .0001by extra sum of squares.)<sup>24</sup> The GRI has the added advantage that both components are higher when glycemic control is worse. The ideal value is zero for GRI and both the hypoglycemia and hyperglycemia components. This makes for an intuitive graphical display on a two-dimensional grid as in Figures 4 to 6.

We separately assessed goodness-of-fit between the GRI and the clinicians' percentile rankings for CGM tracings




**Figure 3.** Clinicians' percentile rankings (lower is better) versus time in range (higher is better). When time in range was approximately 50%, the clinicians' percentile ranking could be as high as 97 (A) or as low as 44 (B). Similarly, when time in range was approximately 70%, the clinicians' percentile ranking could be as high as 62 (C) or as low as 25 (D). Abbreviations: RMS, root mean square error; CGM, continuous glucose monitor; TIR, time in target range.

from each of the four patient categories. The fit for the individual patient categories was similar to the fit for the overall group.

We evaluated several models for matching the clinicians' percentile rankings. Overall, the GRI was the best model identified.

# Graphical Display of Hyperglycemia Versus Hypoglycemia

Since glycemic control is a two-dimensional quantity, the GRI's hypoglycemia and hyperglycemia components can be displayed on a two-dimensional plot called the GRI Grid (Figure 4). We chose to display the hypoglycemia component (0%-100%) on the horizontal axis and the hyperglycemia component (0%-100%) on the vertical axis. A set of diagonal lines divides the graph into five glycemia risk zones (which we label A-E) corresponding to the best (first-20th percentile) to worst (81st-100th percentile) quintiles for overall quality of glycemia. We highlighted two points corresponding to CGM tracings from two persons with T1D, whom we will call P1 and P2, both treated with MDI. Both have similar GRIs (and clinicians' percentile ranking), but one person (P1) had no hypoglycemia on the CGM tracing and the other (P2) had 8% VLow and 7% Low. The TIR for these two CGM tracings was different for P1 versus P2 (31% vs 55%), but because the person with the higher TIR had




**Figure 4.** A Glycemia Risk Index grid showing the hyperglycemia component versus the hypoglycemia component for all 225 CGM tracings. The results for each of the four categories of patients are shown with different symbols. We highlighted individual data points for the CGM tracings from two persons (designated PI and P2) with type I diabetes receiving multiple daily insulin injections. Abbreviations: GRI, Glycemia Risk Index; T1D, type I diabetes; MDI, multiple daily insulin injections; VLow, very low–glucose hypoglycemia (<54 mg/dL; <3.0 mmol/L) (level 2 hypoglycemia); Low, low-glucose hypoglycemia (54-<70 mg/dL; 3.0-<3.9 mmol/L) (level 1 hypoglycemia); High, high-glucose hyperglycemia (>180-250 mg/dL; >10.0-13.9 mmol/L) (level 1 hyperglycemia); VHigh, very high–glucose hyperglycemia (>250 mg/dL; >13.9 mmol/L) (level 2 hyperglycemia); TIR, time in target range (70-180 mg/dL; 3.9-10.0 mmol/L); Hypo, Hypoglycemia Component; Hyper, Hyperglycemia Component; Pump, insulin infusion pump; HCL, hybrid closed loop; T2D, type 2 diabetes.

substantial hypoglycemia, the GRIs are almost the same (76 and 75, respectively).

The grid also enables the user to track sequential changes within an individual. Figure 5 shows a hypothetical patient's progression over five time periods (time 1-time 5). Between time 1 and time 2, TIR worsened by decreasing from 46% to 40%. However, the GRI between the same two periods improved from 90 to 75. At time 1, the hypoglycemia and hyperglycemia components are 16% and 26%. For time 2, they are 6% and 35%. In this example, the treatment was adapted to reduce the risk of hypoglycemia, resulting in much less hypoglycemia, slightly less time in target range, and more hyperglycemia: VLow decreased from 8% to 3% and Low decreased from 10% to 4%. The amount of time in

VLow and Low ranges combined and the amount of time in the VHigh and High ranges were more favorable at time 2 than at time 1, resulting in an improved GRI, even though the TIR worsened. Because GRI accounts for more extreme outof-range times and assigns greater weight to hypoglycemia than to hyperglycemia, an improvement (reduction) in VLow can have more influence than a worsening in TIR. The divergence (improving GRI and worsening TIR) between time 1 and time 2 in this example was followed by progressive improvement in both the GRI and the TIR for time 3, time 4, and time 5.

Data from a multiday or multiweek CGM tracing can be broken down into separate daily or weekly GRIs. These GRIs can then be plotted on a grid to determine whether patterns of



**Figure 5.** The Glycemia Risk Index over time for five different time periods. Legend: Between times I and 2, the TIR worsened by decreasing from 46% to 40%. However, the GRI improved from 90 to 75. For time I, the hypoglycemia/hyperglycemia components are 16%/26%. For time 2, they are 6%/35%. Adjustment to reduce hypoglycemia could increase hyperglycemia. Abbreviations: GRI, Glycemia Risk Index; TIR, time in range; Hypo, hypoglycemia component; Hyper, hyperglycemia component.

glycemia during specific days or weeks of a measurement period differ from patterns during other time periods.


The mean GRI was lowest in the T1D HCL category (mean GRI = 26), highest in the T1D MDI category (mean GRI = 78) and similar in the T1D Pump (mean GRI = 43) and T2D MDI (mean GRI = 52) categories (Figure 6). The T1D Pump and T2D MDI groups had similar GRIs, but the T1D Pump group had more hypoglycemia and less hyperglycemia than the T2D MDI group. For the T1D Pump group, mean hypoglycemia and hyperglycemia components were 3% and 21%. In the T2D MDI group, they were 2% and 28%.

The GRI Grid displays both hypoglycemia risk and hyperglycemia exposure. This plot allows for an individual patient's risks to be monitored sequentially over time and for a population of patients to be monitored for identifying those who require additional treatment.

### Discussion

The GRI is a composite CGM metric of glycemic risk. This index (1) reflects both the essential hypoglycemia and hyperglycemia components, (2) weights extreme hypoglycemia or hyperglycemia more than less extreme hypoglycemia or hyperglycemia, and (3) correlates with clinician rankings more closely than other models we considered, such as TIR or TIR combined with TBR.

A useful feature of the GRI's hypoglycemia and hyperglycemia components is that they can be plotted together on a grid with the origin for both located in the lower left corner and extreme values in the upper right corner. The GRI can be reported and plotted longitudinally for one patient or crosssectionally for a group of patients. Using only a single index may be more attractive to some clinicians, but understanding the two actionable dimensions of hypoglycemia and hyperglycemia, when paired with a glucose profile, should permit



**Figure 6.** The median and IQR for the Hyperglycemia Component and Hypoglycemia Component for the four patient categories and overall. Abbreviations: IQR, interquartile range; GRI, Glycemia Risk Index; TID, type I diabetes; MDI, multiple daily insulin injections; HCL, hybrid closed loop; Pump, insulin infusion pump; T2D, type 2 diabetes.

and facilitate more appropriate adjustments in therapy. Perhaps a GRI above a chosen level should prompt detailed review of the AGP report or referral to a diabetes specialist.


### Comparison With Time in Range

TIR is an easy-to-understand, well-established metric for the quality of glycemia.<sup>27</sup> Both TIR and the GRI can be calculated for any desired time period. An obvious difference between the GRI and TIR is that the GRI is higher when glycemia is worse and the TIR is higher when glycemia is better. Both are on a 0 to 100 scale. If the pattern of glycemia is poor, then the grid portrayal of the GRI indicates whether the problem is too much hypoglycemia, too much hyperglycemia, or too much of both. A glucose profile can then be used to determine an action. TIR as a single measurement does not indicate whether the out of range readings are generally too low or too high, and if they are too low or too high, then TIR does not weight (as experienced clinicians do) hypoglycemia as more significant than hyperglycemia. Also,

TIR does not weight extreme deviations from the target range more heavily than less extreme deviations.

TIR and TBR can be used together effectively to express the quality of glycemia.9,26 However, compared with the GRI's components, use of a combination of TIR and TBR did not provide as good a fit to clinician rankings. The clinicians distinguished between time spent in the very high versus the high glucose range and, to a lesser extent, between time spent in the very low versus the low glucose range. Also, from an intuitive or visual standpoint, we believe that many clinicians would prefer to use a single-index, linear combination of hypoglycemia and hyperglycemia components, both of which are worse when high, than a combination of TBR and TIR, one of which (TBR) is worse when high and one of which (TIR) is worse when low. Moreover, from a control engineering perspective, TIR and TBR do not combine in a well-defined cost function for the purposes of automated optimization to a target set point.

A clinician or researcher might wish to use GRI in addition to TIR as a summary statistic to understand a set of



**Figure 7.** The Glycemia Risk Index weights glucose abnormalities according to a five-step function. The five-step weighting process for the GRI is in contrast to the smooth LBGI/ HBGI risk function introduced by Kovatchev<sup>30</sup> and Kovatchev et al.,<sup>31</sup> Abbreviations: GRI, Glycemia Risk Index; LBGI, low blood glucose index; HBGI, high blood glucose index.

CGM data from a different perspective than that of TIR. A correlation between TIR and long-term complications has been demonstrated.<sup>28</sup> GRI is a new metric and has not yet been studied for its association with outcomes. In view of the high correlation between TIR and GRI for the present data set, it is highly likely that similar high correlations will be found between GRI and long-term complications.

# Comparison With Other Metrics of Glycemic Control

Plotting the GRI's hyperglycemia component (0%-100%) on the vertical axis and hypoglycemia component (0%-100%) on the horizontal axis with a set of diagonal lines creates a graph similar to one created by Rodbard.<sup>29</sup> The diagonal lines on the display of a GRI grid as in Figure 4 predict the clinicians' percentile rankings, whereas the diagonal lines in Rodbard correspond to specified times in range. Rodbard displayed percent of time <80 mg/dL on the horizontal axis, while the GRI's hypoglycemic component gives a weight of 0.8 to less extreme hypoglycemia (54-<70 mg/dL) relative to extreme hypoglycemia (<54 mg/dL). Similarly, Rodbard displayed percent of time >180 mg/dL on the vertical axis, while the GRI's hyperglycemia component uses a lower weight for less extreme hyperglycemia (>180-250 mg/dL) as 0.5 of the weight for extreme hyperglycemia (>250 mg/dL).

The GRI uses a simple five-step weighting function for glucose values using the AGP glucose boundaries of 54, 70, 180, and 250 mg/dL. It weights VLow:Low:VHigh:High in the ratio 3.75:3:2:1. This increased weighting of extreme

glucose values is characteristic of risk indexes used by engineers in algorithm development, which typically assign higher penalties for greater deviations from a safe state. In 1997, Kovatchev et al. introduced the Low Blood Glucose Index/High Blood Glucose Index (LBGI/HBGI) based on a smooth risk function to which the GRI step function roughly corresponds (Figure 7).<sup>30,31</sup> A similar kind of risk function was developed by several other investigators.<sup>8,32</sup>

### Limitations

As part of this research effort, we invited 80 experts in CGM clinical research and clinical practice from six continents to complete a survey linking quantitative measures with clinical assessments. We asked the experts to create ten zones of clinical performance from worst to best for each of the seven CGM metrics. The zones did not necessarily have to be equal in width. The experts' ten zones for each metric were then averaged to assign levels of appeal for each of the analytic measures and make it possible to compare one measure with another in terms of quality of glycemia. The subsequent analysis was performed using both the "raw" CGM metrics and the experts' scaled scores. Since similar regression results were obtained whether we used the "raw" CGM parameters in standard units or the expert-scaled metrics, we decided to use the original measurements. An analysis of the scaling by experts will be published elsewhere.

The data set of CGM tracings used to develop the GRI came from clinical trials that included four different types of insulin-treated adult patients using CGM and may not be representative of tracings in other clinical populations. For example, the GRI would not be applicable to the quality of glycemia in pregnant women or children until it has been validated in these populations. The GRI is not a substitute for looking at individual metrics but rather is a summary or screening score. It can be used either to supplement individual metrics or determine who warrants either review of individual metrics or referral to an expert in optimizing glycemic control. As with each of the summary measures in the AGP, the GRI does not distinguish by time of day. In most cases, specific treatment decisions will require differentiating between daytime and nighttime or between preprandial and postprandial patterns of glycemia, which can be seen in a composite glucose profile or series of daily glucose profiles that make up the composite profile. The GRI is based on the average ratings of experienced clinicians who were specifically recruited for this study by experts in research and clinical use of CGMs from six continents. A different sample of experienced clinicians (whether by geography or specialty) might have produced a different set of rankings. Finally and most importantly, the GRI is based on clinician rankings, not clinical outcomes. Subsequent studies will be needed to determine how well the GRI predicts outcomes.

### Applications

The GRI is a statistic expressing the quality of glycemia that is expected to have value in four contexts. These are (1) managing the health care of CGM users in conjunction with an AGP report, (2) identifying individuals within a population who are most in need of further glycemic optimization, (3) developing algorithms for automated insulin dosing systems to quantify glycemic patterns, so clinicians, statisticians, and other researchers can choose which trade-offs to make, and (4) predicting outcomes in long term studies of interventions intended to decrease risks of complications, both according to the GRI score and the hypoglycemia and hyperglycemia components as potentially independent variables.

# Conclusion

In conclusion, we have identified a pair of essential components of glycemic control, one related to hypoglycemia and one related to hyperglycemia. We also introduce a composite metric, the GRI, that describes the quality of glycemia in a CGM tracing. The GRI is a single number weighted according to the risk for hypoglycemia and hyperglycemia and based on the opinions of experienced clinicians. GRI has the potential to become established as a useful statistic for assessing and treating patients, following the quality of glycemia in populations, determining trade-offs for developing algorithms for automated insulin delivery algorithms, and predicting long-term complications in diabetes.

#### Abbreviations

ADA, American Diabetes Association; Adj, Adjusted; AGP, Ambulatory Glucose Profile; CGM, continuous glucose monitor; CV, coefficient of variation (standard deviation of glucose/mean glucose); GRI, Glycemia Risk Index; GMI, Glucose Management Indicator; HCL, hybrid closed loop; IQR, interquartile range; LBGI/HBGI, low blood glucose index/high blood glucose index; MDI, multiple daily insulin injections; MG, mean glucose; PCA, principal component analysis; Pump, insulin infusion pump; SD, standard deviation; TAR, time above range (>180 mg/dL; >10.0 mmol/L); TBR, time below range (<70 mg/dL; <3.9 mmol/L); TIR, time in target range (70-180 mg/dL; 3.9-10.0 mmol/L); % of time in specified ranges for glucose: VLow, very low-glucose hypoglycemia (<54 mg/dL; <3.0 mmol/L) (level 2 hypoglycemia); Low, low-glucose hypoglycemia (54-<70 mg/dL; 3.0-<3.9 mmol/L) (level 1 hypoglycemia); High, high-glucose hyperglycemia (>180-250 mg/dL; >10.0-13.9 mmol/L) (level 1 hyperglycemia); VHigh, very high-glucose hyperglycemia (>250 mg/dL; >13.9 mmol/L) (level 2 hyperglycemia); T1D, type 1 diabetes; T2D, type 2 diabetes.

#### Acknowledgements

The authors acknowledge Guillermo Arreaza-Rubin, MD, William T. Cefalu, MD, and Lawrence Fisher, PhD, ABPP, who were on the Glycemia Risk Index Clinical Study Advisory Board. The authors thank Roy Beck, MD, PhD, for providing CGM tracings and Richard Bergenstal, MD, for providing AGP reports for the tracings

used in this study. The authors thank Annamarie Sucher-Jones for her expert editorial assistance.

### **Declaration of Conflicting Interests**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D.C.K. is a consultant to AI Health, Dexcom, Eli Lilly, EOFlow, Integrity, Lifecare, Medtronic, Novo, Roche Diagnostics, Rockley Photonics, and Thirdwayv. D.R. is a consultant to Eli Lilly & Co. Inc. and Better Therapeutics, Inc. He has previously provided consulting services to multiple companies and organizations that produce glucose meters, continuous glucose monitors, insulin pumps, closed-loop systems, software applications, clinical decision support systems, and other technologies for management of patients with diabetes. D.K. has received remuneration for participation in Advisory Boards from Sanofi, Novo Nordisk, and Abbott Diabetes Care. He also has received research support from Novo Nordisk and Abbott Diabetes Care and has financial interests in Glooko, Hi.Health and SNAQ. DA has received speaker's honoraria from Lilly Diabetes, Xeris Pharmaceuticals, and Zealand Pharma. He has received consulting fees from Ascensia Diabetes Care, Roche Diagnostics, and Senseonics. A.L.P. reports participation on an advisory board for Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Medscape, Novo Nordisk, Vertex, and Zealand Research. She reports support from Dexcom and Insulet and receives donated devices from Abbott Diabetes Care. She has stock options with Omada Health and Teladoc. JJS has received remuneration for participation in one Advisory Board meeting for Dexcom. G.E.U. reports research funds to Emory University from Astra Zeneca and Dexcom. NYX is a consultant to Abbott Diabetes Care. K.T.N. is a consultant to Abbott Diabetes Care. G.S. reports educational grants from Abbott Diabetes Care and Sanofi. He also reports research grants from Abbott Diabetes Care. T.S.B. reports research support from Abbott Diabetes, Abbott Rapid Diagnostics, Bioling, Capillary Biomedical, Dexcom, Eli Lilly, Kowa, Livongo, MannKind, Medtronic, Novo Nordisk, REMD, Sanofi, Sanvita, Senseonics, Viacyte, vTv Therapeutics, and Zealand Pharma. He also reports consulting honoraria from Abbott, CeQur, Lifescan, MannKind, Medtronic, Novo, and Sanofi, as well as speaking Honoraria from BD, Medtronic, Sanofi. P.-Y.B. has received speaker honoraria from Abbott, Roche, Eli Lilly, Novo Nordisk, and Sanofi, and served on advisory board panels for Abbott, Diabeloop, Roche, Medtronic, Dexcom, Insulet, LifeScan, Eli Lilly, Novo Nordisk, and Sanofi. Th.B. reports research support from Lilly, Novo, Dexcom, Tandem, Abbott, and Viacyte. He reports research site research support from Medtronic. He is a speaker for Lilly, Novo, BI, AZ, and Zealand. J.R.C. has a financial interest in Pacific Diabetes Technologies Inc., a company that may have a commercial interest in the results of this type of research and technology. J.R.C. also reports advisory board participation for Zealand Pharma, Novo Nordisk, Insulet, and AstraZeneca, and her institution has received research funding from Dexcom. P.C. has received personal fees from Medtronic, Dexcom, Abbott, Glooko, Insulet, Sanofi, Lilly, and Novo Nordisk. He has received research support from Abbott, Dexcom, Medtronic, and Novo Nordisk. M.A.C. is the Chief Medical Officer at Glooko. He reports material grant support from Abbott Diabetes Care and Dexcom for investigator-initiated studies. T.D. has received speaker's honoraria and research

support from and has consulted for Abbott, AstraZeneca, Boehringer, Dexcom, Lilly, Medtronic, Novo Nordisk, Roche, Sanofi, and Ypsomed and is a shareholder of DreaMed Ltd. F.J.D. reports equity, licensed IP, and is a member of the Scientific Advisory Board of Mode AGC. K.M.D. reports research support from Dexcom, Abbott, Sanofi, and Viacyte. She has consulted for Dexcom, Eli Lilly, and Boehringer Ingelheim. She reports honoraria from Elsevier, Medscape, Academy for Continued Healthcare Learning, Cardiometabolic Health Conference, UptoDate. S.V.E. is a medical advisor for Lilly, Sanofi, AZ, Brightsight, and BOD Senseonics. J.C.E. is a paid consultant for AI Health. AI Health played no role in the design, execution, analysis, or write up of this work. AI Health did not play a role in the decision to publish this manuscript and had no editorial input. J.C.E. receives grant support from the Food and Drug Administration under award number P50FD006425 for The West Coast Consortium for Technology & Innovation in Pediatrics, and by grants UL1TR001855 and UL1TR000130 from the National Center for Advancing Translational Science (NCATS) of the US National Institutes of Health. The funding sources had no involvement in the development of this manuscript or in the decision to submit the paper for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the FDA or the NIH. G.A.F. has disclosures with 180 LifeScience, Abvance, Adocia, American Federation for Aging Research, Aerami, ALMS, Amolyt, Baker Heart & Diabetes (formerly Cardiora), Berg, Biocon, CarThera, Checkpoint, Diamyd, Diasome, Entera Bio, Enterin, Fortress, Glyscend, Hagar, IM Therapeutics, i2O, Innoneo, Mars Symbioscience, Linear, MMD, Northwestern University, NuSirt, Oberland, Oramed, Orgenesis, Pano, RenovoRx, Rivus, SFC Fluidics, Stalicla, Surf Bio, TixiMED, Unify, Veroscience, Verthermia, Zucara. GPF reports research support from Medtronic, Dexcom, Insulet, Tandem, Abbott, Lilly, and Beta Bionics. He reports speaking/consulting/advisory board fees from Medtronic, Dexcom, Tandem, Insulet, Abbott, Lilly, and Beta Bionics. GF is general manager and medical director of the Institute for Diabetes Technology (Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany), which carries out clinical studies, for example, with medical devices for diabetes therapy on its own initiative and on behalf of various companies. GF/IDT have received speakers' honoraria or consulting fees from Abbott, Ascensia, Berlin Chemie, Beurer, BOYDsense, CRF Health, Dexcom, i-SENS, Lilly, Metronom, MySugr, Novo Nordisk, Pharmasens, Roche, Sanofi, Sensile, Terumo, and Ypsomed. R.J.G. received research support to Emory University for investigator-initiated studies from Novo Nordisk, Dexcom and Eli Lilly and consulting fees from Abbott Diabetes Care, Sanofi, Valeritas, Eli Lilly, Novo Nordisk, and Weight Watchers, outside of this work. R.J.G. is partially supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) under Award Numbers P30DK111024 (RJG), K23DK123384 (RJG). AMG has been a speaker for Sanofi, Medtronic, Abbott, Elli Lilly, and Novo Nordisk. L.H. is a consultant for a number of companies that are developing novel diagnostic and therapeutic options for diabetes treatment. He is a shareholder of the Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany. I.B.H. reports research support from Medtronic Diabetes, Insulet, and Beta Bionics. He has consulted for Abbott, Roche, Bigfoot, and GWave.

T.D.H. is on the Advisory Board for Acella and Horizon therapeutics for which he receives no financial compensation. J.H.J. has received remuneration for participation in Advisory Boards from Sanofi, Novo Nordisk, Abbott Diabetes Care, Medtronic and Eli Lilly. He also has received research support from Novo Nordisk. SRJ has disclosures with Abbott, Novartis, Novo Nordisk, Zydus Cadila, Twinhealth, Marico, Franco Indian, USV, BI, AstraZeneca, Roche Diabetes Care, Lifescan, BayerZydus, and Glenmark. M.J. reports advisory fees, speaker fees and/or research funds from Abbott, Air Liquide Santé International, Amgen, Astrazeneca, Bayer, BMS, Boehringer Ingelheim, Dexcom, Glooko, Lifescan, Lilly, Medtronic, MSD, Nestle HomeCare, Novonordisk, Orkyn, Roche Diabetes, Sanofi, Vitalaire, and Voluntis. S.K.K. receives grant support from the UCSF Nutrition and Obesity Research Center (NIH P30 DK098722) and is an advisor to Yes Health, Suggestic, and Signos. R.A.L. is a consultant for Abbott Diabetes Care, Bioling, Capillary Biomedical, Deep Valley Labs, Gluroo, Provention Bio, and Tidepool. M.C.L. reports research funding from Dexcom. L.A.L. has received research funding from, has acted as an adviser to, and/or has provided CME on behalf of Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lexicon, Merck, Novo Nordisk, Pfizer, Sanofi, and Servier. M.L. has received research grants from Eli Lilly and Novo Nordisk and has been a consultant for Astra Zeneca, Boehringer Ingelheim, Eli Lilly and Novo Nordisk. M.L.L. is an Advisory Board member for DiabetesWise PRO and dQ&A. J.K.M. is a member of the advisory board of Boehringer Ingelheim, Eli Lilly, Medtronic, Prediktor A/S, Roche Diabetes Care and Sanofi, and received speaker honoraria from Abbott Diabetes Care, AstraZeneca, Dexcom, Eli Lilly, Medtronic, Merk Sharp & Dohme, Novo Nordisk A/S, Roche Diabetes Care, Sanofi, Servier, and Takeda. UM reports research funding from Clementia Pharmaceutical and is an advisor for Ryse Health. J.M. is a full-time employee at Glytec. J.D.M. is a consultant/speaker for Medtronic Diabetes and an advisor for MannKind, Inc. He reports grant support from Dexcom, Inc. V.M. has acted as a consultant and speaker, received research or educational grants from Abbott, Astra Zeneca, Boehringer Ingelheim, Dr. Reddy's Laboratories, Johnson & Johnson, LifeScan, Lilly, MSD, Novartis, Novo Nordisk, Roche Diabetes Care India Pvt. Ltd, Sanofi-Aventis, USV Private Limited, and from other Indian pharmaceutical companies. JHN is a consultant for Abbott, Dexcom, and Roche. He reports research support and speaker honorarium from Abbott, and speaker honorarium from Roche. KN received funding for her institution for participating in advisory boards from Medtronic, Convatec, and Novo Nordisk and for lecturing from Sanofi, Novo Nordisk, Medtronic, and Dexcom. Her institution received funding for studies she performed from Zealand Pharma, RSP Systems, Novo Nordisk, Medtronic and Dexcom. F.J.P. reports research support from Merck, Dexcom, and Insulet. He is a consultant for Boehringer Ingelheim, Dexcom, and AI Health. A.P.-T. reports that Scripps Health receives fees for advising services with no transfer to author. M.P. reports grants/research support to his Institute from Medtronic, Novo Nordisk, Roche, Eli Lilly, Sanofi, Pfizer, Insulet, Opko, Dexcom, DOMPE DreaMed-Diabetes, and NG Solutions. He reports honoraria or consultation fees from Sanofi, Medtronic, Novo Nordisk, Eli Lilly and Pfizer. He is on the Advisory Board for Sanofi, Medtronic, AstraZeneca, Eli Lilly, Insulet, Pfizer, and DOMPE. He is a stock shareholder in NG Solutions Ltd. And DreaMed-Diabetes Ltd. He is a consultant for Qulab Medical.

W.H.P. is a consultant for Dexcom and Abbott Diabetes Care. S.J.R. is an inventor on patents related to the bionic pancreas technology that are assigned to Massachusetts General Hospital and licensed to Beta Bionics; has received honoraria and/or travel expenses for lectures from Novo Nordisk, Roche, and Ascensia; serves on the scientific advisory boards of Unomedical and Companion Medical; has received consulting fees from Beta Bionics, Novo Nordisk, Senseonics, and Flexion Therapeutics; has received grant support from Zealand Pharma, Novo Nordisk, and Beta Bionics; and has received in-kind support in the form of technical support and/or donation of materials from Zealand Pharma, Ascensia, Senseonics, Adocia, and Tandem Diabetes. V.N.S.'s employer received grants from Sanofi, Dexcom, Insulet, Abbott, Novo Nordisk, and Eli Lilly. V.N.S. received honorarium/consulting fees through University of Colorado from Dexcom, Insulet, Sanofi, and Medscape. These disclosures are outside the submitted work. J.L.S. has conducted clinical trials for Eli Lilly, Insulet, and Medtronic and has received in-kind support for research studies from Dexcom and Medtronic. She has consulted for Eli Lilly, Lexicon, Medtronic, and Sanofi. She has been a member of advisory boards for Bigfoot Biomedical, Cecelia Health, Eli Lilly, Insulet, the T1D Fund, and Vertex. K.S. is a full-time employee of University of North Carolina at Chapel Hill and has received grants from Arkray Inc., Dexcom Inc., Terumo Corp., and PTS Inc. E.K.S. reports that this work was supported in part by a VA MERIT award from the US Department of Veterans Affairs Clinical Sciences Research and Development Service (1101CX001825). E.K.S. has received unrestricted research support from Dexcom (to the Baltimore VA Medical Center and to the University of Maryland)

Baltmore VA Medical Center and to the University of Maryland) for the conduction of clinical trials. A.W. reports research support from Novo Nordisk, UnitedHealth Group, and Eli Lilly. E.E.W. is an advisor, consultant and speaker for Abbott Diabetes Care and Bayer, an advisor and speaker for Boehringer Ingelheim and Sanofi, a speaker for Eli Lilly, and an advisor Medtronic. B.K. reports research support handled by the University of Virginia from Dexcom, Novo Nordisk, Tandem Diabetes Care. He also reports patent royalties handled by the University of Virginia from Dexcom, Johnson & Johnson, Novo Nordisk, and Sanofi. He has received presentation honoraria from Tandem. J.W., M.K., C.L., D.L., M.S.D.A., M.E.A.-S., G.A.-P., A.B., Ta.B., S.Y.B., B.W.B., M.D.B., J.G.C., K.Y.C., K.L.C., C.B.C., A.D., N.E., H.A.G., R.H., L.J., L.L., K.M.M., B.M., N.N.M., A.M., D.N.N., T.P., R.P.-B., G.R., E.-J.R., D.W., K.W., M.E.W., H.W., and M.Z. have nothing relevant to disclose.

### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Diabetes Technology Society, which received no external funding and paid all costs for conducting the study.

# **ORCID** iDs

David C. Klonoff (D https://orcid.org/0000-0001-6394-6862 Jing Wang (D https://orcid.org/0000-0002-4012-0977 David Rodbard (D https://orcid.org/0000-0002-5547-3564 Michael A. Kohn (D https://orcid.org/0000-0001-5459-5044 Chengdong Li (D https://orcid.org/0000-0001-5330-9624 Dorian Liepmann (D https://orcid.org/0000-0002-2591-4031 David Kerr (D https://orcid.org/0000-0003-1335-1857 David Ahn (D) https://orcid.org/0000-0002-8941-8459 Anne L. Peters (D) https://orcid.org/0000-0003-0520-0776 Guillermo E. Umpierrez (D) https://orcid.org/0000-0002-3252-5026 Jane Jeffrie Seley (D) https://orcid.org/0000-0003-1582-4320 Nicole Y. Xu (D) https://orcid.org/0000-0001-9353-8819 Kevin T. Nguyen (D) https://orcid.org/0000-0001-9102-6537 Gregg Simonson (D) https://orcid.org/0000-0001-5561-2547 Michael S. D. Agus (D) https://orcid.org/0000-0001-6454-6828 Mohammed E. Al-Sofiani (D) https://orcid.org/0000-0003-4420 -9378

Gustavo Armaiz-Pena D https://orcid.org/0000-0001-9652-9010 Timothy S. Bailey D https://orcid.org/0000-0003-4178-3462 Ananda Basu D https://orcid.org/0000-0003-4166-6741 Tadej Battelino D https://orcid.org/0000-0002-0273-4732 Sewagegn Yeshiwas Bekele D https://orcid.org/0000-0002-8153 -7672

Pierre-Yves Benhamou D https://orcid.org/0000-0003-4378-0468 B. Wayne Bequette (D) https://orcid.org/0000-0002-6472-1902 Thomas Blevins (D) https://orcid.org/0000-0003-3746-9606 Marc D. Breton (D) https://orcid.org/0000-0001-7645-2693 Jessica R. Castle D https://orcid.org/0000-0003-1179-5374 James Geoffrey Chase (i) https://orcid.org/0000-0001-9989-4849 Kong Y. Chen (D) https://orcid.org/0000-0002-0306-1904 Pratik Choudhary D https://orcid.org/0000-0001-7635-4735 Mark A. Clements D https://orcid.org/0000-0002-2368-0331 Kelly L. Close (D) https://orcid.org/0000-0001-7332-1380 Curtiss B. Cook (D) https://orcid.org/0000-0001-5885-9959 Francis J. Doyle III D https://orcid.org/0000-0002-3293-9114 Andjela Drincic 问 https://orcid.org/0000-0001-8365-7662 Kathleen M. Dungan (D https://orcid.org/0000-0003-1289-1595 Steven V. Edelman (D https://orcid.org/0000-0002-0760-9332 Niels Ejskjaer (D) https://orcid.org/0000-0003-3749-3403 Juan C. Espinoza (p) https://orcid.org/0000-0003-0513-588X G. Alexander Fleming (D https://orcid.org/0000-0002-6549-0288 Gregory P. Forlenza D https://orcid.org/0000-0003-3607-9788 Guido Freckmann D https://orcid.org/0000-0002-0406-9529 Rodolfo J. Galindo D https://orcid.org/0000-0002-9295-3225 Ana Maria Gomez (D) https://orcid.org/0000-0002-5273-7018 Hanna A. Gutow (D https://orcid.org/0000-0001-9067-898X Lutz Heinemann (D https://orcid.org/0000-0003-2493-1304 Irl B. Hirsch (D) https://orcid.org/0000-0003-1675-8417 Thanh D. Hoang (D https://orcid.org/0000-0001-7437-5604 Roman Hovorka D https://orcid.org/0000-0003-2901-461X Johan H. Jendle (D) https://orcid.org/0000-0003-1025-1682 Linong Ji (D) https://orcid.org/0000-0003-1305-1598 Shashank R. Joshi D https://orcid.org/0000-0002-0990-5821 Michael Joubert D https://orcid.org/0000-0002-8731-7355 Suneil K. Koliwad D https://orcid.org/0000-0002-7367-1054 Rayhan A. Lal 问 https://orcid.org/0000-0002-8055-944X M. Cecilia Lansang D https://orcid.org/0000-0002-7364-5550 Wei-An (Andy) Lee (D https://orcid.org/0000-0002-2928-7338 Lalantha Leelarathna (D) https://orcid.org/0000-0001-9602-1962

Lawrence A. Leiter D https://orcid.org/0000-0002-1040-6229 Marcus Lind D https://orcid.org/0000-0002-3796-9283 Michelle L. Litchman D https://orcid.org/0000-0002-8928-5748 Julia K. Mader D https://orcid.org/0000-0001-7854-4233 Katherine M. Mahoney D https://orcid.org/0000-0002-5857-386X Boris Mankovsky D https://orcid.org/0000-0001-8289-3604 Umesh Masharani D https://orcid.org/0000-0002-3269-804X Nestoras N. Mathioudakis D https://orcid.org/0000-0002-0210 -655X

Alexander Mayorov D https://orcid.org/0000-0001-5825-3287 Jordan Messler (D) https://orcid.org/0000-0002-3080-6940 Joshua D. Miller (D) https://orcid.org/0000-0001-9512-461X Viswanathan Mohan D https://orcid.org/0000-0001-5038-6210 James H. Nichols (D) https://orcid.org/0000-0002-3652-1612 Kirsten Nørgaard D https://orcid.org/0000-0003-1620-8271 David N. O'Neal (D https://orcid.org/0000-0002-0870-4032 Francisco J. Pasquel (D) https://orcid.org/0000-0002-3845-6703 Athena Philis-Tsimikas (D) https://orcid.org/0000-0002-3986-9630 Thomas Pieber D https://orcid.org/0000-0003-3554-0405 Moshe Phillip (D) https://orcid.org/0000-0002-6616-5612 William H. Polonsky n https://orcid.org/0000-0001-9064-6144 Rodica Pop-Busui D https://orcid.org/0000-0002-2042-1350 Gerry Rayman (D) https://orcid.org/0000-0003-3331-7015 Eun-Jung Rhee (D) https://orcid.org/0000-0002-6108-7758 Steven J. Russell 问 https://orcid.org/0000-0001-8423-5891 Viral N. Shah (D) https://orcid.org/0000-0002-3827-7107 Jennifer L. Sherr D https://orcid.org/0000-0001-9301-3043 Koji Sode (D) https://orcid.org/0000-0002-9833-2091 Elias K. Spanakis (D) https://orcid.org/0000-0002-9352-7172 Deborah J. Wake (D) https://orcid.org/0000-0003-4376-6973 Kayo Waki 问 https://orcid.org/0000-0003-0046-2523 Amisha Wallia (D) https://orcid.org/0000-0002-3183-4062 Melissa E. Weinberg D https://orcid.org/0000-0003-2723-5865 Howard Wolpert D https://orcid.org/0000-0001-9771-6344 Eugene E. Wright (D) https://orcid.org/0000-0003-0796-0496 Mihail Zilbermint in https://orcid.org/0000-0003-4047-7260 Boris Kovatchev n https://orcid.org/0000-0003-0495-3901

#### **Supplementary Material**

Supplementary Material for this article is available online.

#### References

- Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2021;44(11):2589-2625.
- Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes. *JAMA*. 2021;325(22):2273-2284.

- Giglio RV, Stoian AP, Haluzik M, et al. Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. *Biochim Biophys Acta Mol Basis Dis.* 2021;1867(8):166148.
- American Diabetes Association Professional Practice Committee. 6. Glycemic targets: standards of medical care in diabetes—2022. *Diabetes Care*. 2022;45(suppl 1):S83-S96.
- AGP Report. Welcome to AGP report. Date unknown. http:// www.agpreport.org/agp/. Accessed December 5, 2021.
- Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. *Diabetes Care*. 2017;40(12):1631-1640.
- Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. *J Diabetes Sci Technol*. 2013;7(2):562-578.
- Rodbard D. Metrics to evaluate quality of glycemic control: comparison of time in target, hypoglycemic, and hyperglycemic ranges with "risk indices." *Diabetes Technol Ther*. 2018;20(5):325-334.
- 9. Rodbard D. Quality of glycemic control: assessment using relationships between metrics for safety and efficacy. *Diabetes Technol Ther*. 2021;23(10):692-704.
- Nguyen M, Han J, Spanakis EK, Kovatchev BP, Klonoff DC. A review of continuous glucose monitoring-based composite metrics for glycemic control. *Diabetes Technol Ther*. 2020;22(8):613-622.
- Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. *BMJ*. 2007;334(7597):786.
- Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. *JAMA*. 2017;317(4):371-378.
- Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. *N Engl J Med.* 2019;381(18):1707-1717.
- Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. *Diabetes Care*. 2017;40(4):538-545.
- Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. *Ann Intern Med.* 2017;167(6):365-374.
- Alvo M, Cabilio P. On the balanced incomplete block design for rankings. *Ann Stat.* 1991;19(3):1597-1613. https://projecteuclid.org/journals/annals-of-statistics/volume-19/issue-3/On-the-Balanced-Incomplete-Block-Design-for-Rankings/10.1214/ aos/1176348264.full. Accessed April 17, 2021.
- MacDonald JA, Hout MC, Schmidt J. An algorithm to minimize the number of blocks in incomplete block designs. *Behav Res Methods*. 2020;52(4):1459-1468.
- Bose RC. ON THE CONSTRUCTION OF BALANCED INCOMPLETE BLOCK DESIGNS. Ann Eugen. 1939;9(4): 353-399.
- Guyon I, Weston J, Barnhill S, et al. Gene Selection for Cancer Classification using Support Vector Machines. *Mach Learn.* 2002;46:389-422. https://doi.org/10.1023/A:1012487302797

- Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. *J Stat Softw.* 2010;33(1):1-22. http://www.jstatsoft.org/v33/i01/. Accessed December 22, 2021.
- Kursa MB, Rudnicki WR. Feature selection with the Boruta package. J Stat Softw. 2010;36(11):1-13. http://www.jstatsoft. org/v36/i11/. Accessed January 25, 2022.
- Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. https://search.ebscohost.com/login.asp x?direct=truescope=sitedb=nlebkdb=nlabkAN=1619230. Published 2017. Accessed January 25, 2022.
- Therneau T, Atkinson B, Ripley B. rpart: recursive partitioning and regression trees. https://CRAN.R-project.org/package=rpart. Published 2022. Accessed January 25, 2022.
- Draper NR, Smith H. Applied regression analysis (Wiley series in probability and statistics). 3rd ed. New York: Wiley; 1998.
- Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. *Diabetes Care*. 1998;21(11):1870-1875.

- Bergenstal RM, Simonson GD, Heinemann L. More green, less red: how color standardization may facilitate effective use of CGM data. *J Diabetes Sci Technol*. 2022;16:3-6.
- Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. *Diabetes Care*. 2019;42(8):1593-1603.
- Aleppo G. Clinical application of time in range and other metrics. Diabetes Spectr Publ Am Diabetes Assoc. 2021;34(2):109-118.
- 29. Rodbard D. Evaluating quality of glycemic control: graphical displays of hypo- and hyperglycemia, time in target range, and mean glucose. *J Diabetes Sci Technol*. 2015;9(1):56-62.
- Kovatchev BP. Metrics for glycaemic control—from HbA1c to continuous glucose monitoring. *Nat Rev Endocrinol*. 2017;13(7):425-436.
- Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W. Symmetrization of the blood glucose measurement scale and its applications. *Diabetes Care*. 1997;20(11):1655-1658.
- Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. *Diabetes Technol Ther.* 2009;11(S1):S55-S67.